Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Study of Prostate Cancer Screening - 23-Year Follow-up.

The New England journal of medicine·2025
Same author

Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.

European urology·2023
Same author

Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.

HGG advances·2022
Same author

Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial.

European urology·2020
Same author

Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer.

Urology·2020
Same author

Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.

European urology·2020
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

Baseline prostate-specific antigen testing at a young age.

Stacy Loeb1, H Ballentine Carter, William J Catalona

  • 1Department of Urology, New York University School of Medicine, New York, NY, USA. stacyloeb@gmail.com

European Urology
|August 25, 2011
PubMed
Summary
This summary is machine-generated.

Baseline prostate-specific antigen (PSA) testing in younger men predicts future prostate cancer risk and outcomes. Early PSA levels help stratify risk and guide screening protocols for better prostate cancer management.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Related Experiment Videos

Last Updated: May 30, 2026

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • Prostate cancer screening, particularly the optimal age for prostate-specific antigen (PSA) testing, remains a subject of debate.
  • Previous research has explored the utility of initial PSA measurements taken at younger ages.

Purpose of the Study:

  • To conduct a literature review on baseline PSA testing in men aged 60 years or younger.
  • To evaluate the predictive value of early PSA levels for prostate cancer risk and prognosis.

Main Methods:

  • A comprehensive PubMed search was performed for English-language studies.
  • Literature focused on baseline PSA and prostate cancer published up to April 2011 was included.

Main Results:

  • Median PSA levels in men aged 40-59 typically range from 0.4 to 1.0 ng/ml.
  • Baseline PSA levels predict future prostate cancer diagnosis, with higher levels indicating increased risk over 20-25 years.
  • Elevated early PSA is linked to higher risks of aggressive cancer, metastasis, and cancer-specific mortality.

Conclusions:

  • Baseline PSA measurements in younger men are significant predictors of future prostate cancer diagnosis and mortality.
  • Early PSA testing can aid in risk stratification and inform personalized prostate cancer screening strategies.